These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9412161)

  • 1. [Cost effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia++ in Spain].
    Sacristán JA; Gómez JC; Salvador-Carulla L
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1997; 25(4):225-34. PubMed ID: 9412161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Economic comparison of olanzapine versus haloperidol in treatment of schizophrenia in France].
    Le Pen C; Lilliu H; Allicar MP; Olivier V; Gregor KJ
    Encephale; 1999; 25(4):281-6. PubMed ID: 10546082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olanzapine. A pharmacoeconomic review of its use in schizophrenia.
    Foster RH; Goa KL
    Pharmacoeconomics; 1999 Jun; 15(6):611-40. PubMed ID: 10538333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
    Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
    JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost-effectiveness clinical decision analysis model for schizophrenia.
    Palmer CS; Revicki DA; Genduso LA; Hamilton SH; Brown RE
    Am J Manag Care; 1998 Mar; 4(3):345-55. PubMed ID: 10178497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol.
    Almond S; O'Donnell O
    Pharmacoeconomics; 2000 Apr; 17(4):383-9. PubMed ID: 10947493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olanzapine: an updated review of its use in the management of schizophrenia.
    Bhana N; Foster RH; Olney R; Plosker GL
    Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of schizophrenic patient functionality on service utilization and cost. Based on a presentation by Sandra L. Tunis, PhD.
    Am J Manag Care; 1999 Jul; 5(10 Suppl):S583-90. PubMed ID: 10539493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.
    Hamilton SH; Revicki DA; Edgell ET; Genduso LA; Tollefson G
    Pharmacoeconomics; 1999 May; 15(5):469-80. PubMed ID: 10537964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.
    De Graeve D; Smet A; Mehnert A; Caleo S; Miadi-Fargier H; Mosqueda GJ; Lecompte D; Peuskens J
    Pharmacoeconomics; 2005; 23 Suppl 1():35-47. PubMed ID: 16416760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia.
    Glazer WM; Johnstone BM
    J Clin Psychiatry; 1997; 58 Suppl 10():50-4. PubMed ID: 9265917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cost-effectiveness clinical decision analysis model for treatment of Schizophrenia.
    Palmer CS; Brunner E; Ruíz-Flores LG; Paez-Agraz F; Revicki DA
    Arch Med Res; 2002; 33(6):572-80. PubMed ID: 12505105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia.
    Tunis SL; Johnstone BM; Gibson PJ; Loosbrock DL; Dulisse BK
    J Clin Psychiatry; 1999; 60 Suppl 19():38-45; discussion 46. PubMed ID: 10507279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.
    Bounthavong M; Okamoto MP
    J Eval Clin Pract; 2007 Jun; 13(3):453-60. PubMed ID: 17518814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol.
    Tunis SL; Croghan TW; Heilman DK; Johnstone BM; Obenchain RL
    Med Care; 1999 Jul; 37(7):678-91. PubMed ID: 10424639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Economic analyses of olanzapine in the treatment of schizophrenia and bipolar disorder].
    Dilla T; Prieto L; Ciudad A; Sacristán JA
    Actas Esp Psiquiatr; 2004; 32(5):269-79. PubMed ID: 15529211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical antipsychotics and formulary decisions.
    Am J Manag Care; 1998 Jan; 4 Suppl():S8-12; discussion S12-4. PubMed ID: 10184948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda.
    Lubinga SJ; Mutamba BB; Nganizi A; Babigumira JB
    Appl Health Econ Health Policy; 2015 Oct; 13(5):493-506. PubMed ID: 25958192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.
    Gibson PJ; Damler R; Jackson EA; Wilder T; Ramsey JL
    Value Health; 2004; 7(1):22-35. PubMed ID: 14720128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model.
    Furiak NM; Ascher-Svanum H; Klein RW; Smolen LJ; Lawson AH; Montgomery W; Conley RR
    Curr Med Res Opin; 2011 Apr; 27(4):713-30. PubMed ID: 21265593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.